Sequencing Therapies for Relapsed Refractory Multiple Myeloma: Bispecifics or CAR T-cell Therapy

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

89Zr-DFO-daratumumab shows activity in identifying and localizing multiple myeloma, even in FDG-non-avid cases, per new phase 2 data.